Illumina (NASDAQ:ILMN) Shares Gap Down on Analyst Downgrade

Illumina, Inc. (NASDAQ:ILMN)’s share price gapped down prior to trading on Friday after JPMorgan Chase & Co. lowered their price target on the stock from $130.00 to $120.00. The stock had previously closed at $133.61, but opened at $125.99. JPMorgan Chase & Co. currently has a neutral rating on the stock. Illumina shares last traded at $120.4710, with a volume of 379,343 shares traded.

ILMN has been the topic of a number of other reports. TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Robert W. Baird set a $137.00 target price on shares of Illumina in a research note on Friday. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Stifel Nicolaus raised their price objective on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, UBS Group reiterated a “neutral” rating and set a $135.00 target price on shares of Illumina in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $130.00.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.60% of the company’s stock.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Illumina reported GAAP/non‑GAAP EPS of $1.35 (beat) and revenue of $1.16B (beat), with ex‑China growth stronger; management highlighted improving margins. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: FY‑2026 guidance mostly in line or better than Street — Illumina guided revenue to $4.5–$4.6B (above some estimates) and non‑GAAP EPS to $5.05–$5.20, signaling modest growth after recent year flatness. The guidance incorporates the SomaLogic acquisition and expected dilution. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: Underlying business trends cited as constructive — analysis points to clinical consumables growth, expansion into multiomics, and margin momentum that could support higher recurring revenue over time. ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum
• Neutral Sentiment: Call/transcript color: management reiterated strategy and provided details on growth drivers and the SomaLogic deal; read the call for guidance assumptions and segment commentary. Illumina Q4 2025 earnings call transcript Seeking Alpha transcript
• Negative Sentiment: Investors disappointed by FY‑2025 flat revenue and cautious tone — FY‑2025 revenue was essentially flat versus prior year, and some investors focused on slower organic growth and the near‑term dilution/costs from the SomaLogic acquisition, prompting selling pressure despite the EPS beat and guidance. Illumina shares tumble as flat revenue disappoints investors
• Negative Sentiment: Analyst/read‑through risk: even with some bullish commentary, markets may be repricing expectations for near‑term top‑line acceleration given mixed signals between margin upside and tepid full‑year growth. Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN)

Institutional Trading of Illumina

A number of institutional investors and hedge funds have recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB increased its stake in shares of Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares during the period. HighPoint Advisor Group LLC grew its position in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the period. Assetmark Inc. raised its stake in shares of Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after buying an additional 96 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Illumina by 0.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after buying an additional 99 shares during the period. Finally, Venturi Wealth Management LLC boosted its stake in shares of Illumina by 4.2% in the fourth quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after buying an additional 99 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 10.4%

The business has a 50 day moving average price of $138.43 and a 200 day moving average price of $116.26. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The stock has a market cap of $18.29 billion, a PE ratio of 21.97, a P/E/G ratio of 1.99 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 32.33% and a net margin of 19.57%.The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.